Ravi K Amaravadi

Summary

Affiliation: University of Pennsylvania
Country: USA

Publications

  1. ncbi request reprint Mouse models address key concerns regarding autophagy inhibition in cancer therapy
    Ravi Amaravadi
    Department of Medicine and Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania
    Cancer Discov 4:873-5. 2014
  2. pmc Autophagy and tumor cell invasion
    Ravi K Amaravadi
    Abramson Cancer Center and Department of Medicine Perelman School of Medicine University of Pennsvylania Philadelphia, PA USA
    Cell Cycle 11:3718. 2012
  3. doi request reprint PUMA: a puzzle piece in chloroquine's antimelanoma activity
    Ravi K Amaravadi
    Department of Medicine, University of Pennsylvania, Philadelphia, PA, USA
    J Invest Dermatol 133:2133-5. 2013
  4. pmc Lys05: a new lysosomal autophagy inhibitor
    Ravi K Amaravadi
    Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA
    Autophagy 8:1383-4. 2012
  5. pmc Autophagy-induced tumor dormancy in ovarian cancer
    Ravi K Amaravadi
    Department of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
    J Clin Invest 118:3837-40. 2008
  6. pmc Principles and current strategies for targeting autophagy for cancer treatment
    Ravi K Amaravadi
    Abramson Cancer Center and Department of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
    Clin Cancer Res 17:654-66. 2011
  7. pmc Autophagy inhibitor Lys05 has single-agent antitumor activity and reproduces the phenotype of a genetic autophagy deficiency
    Quentin McAfee
    Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA
    Proc Natl Acad Sci U S A 109:8253-8. 2012
  8. ncbi request reprint Autophagy inhibition sensitizes colon cancer cells to antiangiogenic and cytotoxic therapy
    Muthu Selvakumaran
    Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania 19014, USA
    Clin Cancer Res 19:2995-3007. 2013
  9. pmc Melanoma adapts to RAF/MEK inhibitors through FOXD3-mediated upregulation of ERBB3
    Ethan V Abel
    Department of Cancer Biology and Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania 19107, USA
    J Clin Invest 123:2155-68. 2013
  10. ncbi request reprint Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth
    Monica Buzzai
    Abramson Family Cancer Research Institute, Department of Cancer Biology, University of Pennsylvania, Philadelphia, PA 19104, USA
    Cancer Res 67:6745-52. 2007

Collaborators

Detail Information

Publications19

  1. ncbi request reprint Mouse models address key concerns regarding autophagy inhibition in cancer therapy
    Ravi Amaravadi
    Department of Medicine and Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania
    Cancer Discov 4:873-5. 2014
    ..Cancer Discov; 4(8); 873-5. ©2014 AACR. See related article by Yang et al., p. 905 See related article by Karsli-Uzunbas et al., p. 914...
  2. pmc Autophagy and tumor cell invasion
    Ravi K Amaravadi
    Abramson Cancer Center and Department of Medicine Perelman School of Medicine University of Pennsvylania Philadelphia, PA USA
    Cell Cycle 11:3718. 2012
    ..Comment on: Macintosh RL, et al. Cell Cycle 2012; 11:2022-9...
  3. doi request reprint PUMA: a puzzle piece in chloroquine's antimelanoma activity
    Ravi K Amaravadi
    Department of Medicine, University of Pennsylvania, Philadelphia, PA, USA
    J Invest Dermatol 133:2133-5. 2013
    ..This finding adds to the unfolding story of CQ's mechanism of action as a cancer therapeutic agent. ..
  4. pmc Lys05: a new lysosomal autophagy inhibitor
    Ravi K Amaravadi
    Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA
    Autophagy 8:1383-4. 2012
    ..Lys05 is therefore a new lysosomal autophagy inhibitor that has potential to be developed further into a drug for cancer and other medical applications...
  5. pmc Autophagy-induced tumor dormancy in ovarian cancer
    Ravi K Amaravadi
    Department of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
    J Clin Invest 118:3837-40. 2008
    ..Since ARHI expression is suppressed in the majority of breast and ovarian cancers but is high in premalignant lesions, ARHI-induced autophagy could be manipulated for therapeutic benefit...
  6. pmc Principles and current strategies for targeting autophagy for cancer treatment
    Ravi K Amaravadi
    Abramson Cancer Center and Department of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
    Clin Cancer Res 17:654-66. 2011
    ..Finally, we describe ongoing clinical trials involving HCQ as a first generation autophagy inhibitor, as well as strategies for the development of novel, more potent, and specific inhibitors of autophagy...
  7. pmc Autophagy inhibitor Lys05 has single-agent antitumor activity and reproduces the phenotype of a genetic autophagy deficiency
    Quentin McAfee
    Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA
    Proc Natl Acad Sci U S A 109:8253-8. 2012
    ..Unlike HCQ, significant single-agent antitumor activity is observed without toxicity in mice treated with lower doses of Lys05, establishing the therapeutic potential of this compound in cancer...
  8. ncbi request reprint Autophagy inhibition sensitizes colon cancer cells to antiangiogenic and cytotoxic therapy
    Muthu Selvakumaran
    Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania 19014, USA
    Clin Cancer Res 19:2995-3007. 2013
    ..We examined the effect of inhibiting autophagy on hypoxic colon cancer cells in vitro and on bevacizumab- and oxaliplatin-treated mouse xenografts in vivo...
  9. pmc Melanoma adapts to RAF/MEK inhibitors through FOXD3-mediated upregulation of ERBB3
    Ethan V Abel
    Department of Cancer Biology and Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania 19107, USA
    J Clin Invest 123:2155-68. 2013
    ....
  10. ncbi request reprint Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth
    Monica Buzzai
    Abramson Family Cancer Research Institute, Department of Cancer Biology, University of Pennsylvania, Philadelphia, PA 19104, USA
    Cancer Res 67:6745-52. 2007
    ..Thus, metformin is selectively toxic to p53-deficient cells and provides a potential mechanism for the reduced incidence of tumors observed in patients being treated with metformin...
  11. pmc The novel SMAC mimetic birinapant exhibits potent activity against human melanoma cells
    Clemens Krepler
    Tumor Microenvironment and Metastasis Program, The Wistar Institute, Philadelphia, PA 19104, USA
    Clin Cancer Res 19:1784-94. 2013
    ..We report on the ability of second mitochondria-derived activator of caspases mimetic, birinapant, which acts as antagonist to cIAP1 and cIAP2, to restore the sensitivity to apoptotic stimuli such as TNF-α in melanomas...
  12. pmc Measurements of tumor cell autophagy predict invasiveness, resistance to chemotherapy, and survival in melanoma
    Xiao Hong Ma
    Division of Hematology Oncology, Department of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA
    Clin Cancer Res 17:3478-89. 2011
    ..The role of autophagy in determining tumor aggressiveness and response to therapy in melanoma was investigated in this study...
  13. ncbi request reprint Diverse cutaneous side effects associated with BRAF inhibitor therapy: a clinicopathologic study
    Emily Y Chu
    Department of Dermatology, Hospital of University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
    J Am Acad Dermatol 67:1265-72. 2012
    ..Similar to the broad-spectrum RAF inhibitor sorafenib, vemurafenib induces development of squamous cell carcinomas and keratoacanthomas as a side effect of therapy...
  14. ncbi request reprint Drug targeting of oncogenic pathways in melanoma
    Leslie A Fecher
    Department of Medicine, Division of Hematology and Oncology, Abramson Cancer Center, University of Pennsylvania, 3400 Spruce Street, 16 Penn Tower, Philadelphia, PA 19104, USA
    Hematol Oncol Clin North Am 23:599-618, x. 2009
    ..The targeting of certain cellular processes, downstream of the common genetic alterations, for which the issues of target and drug validation are somewhat distinct, are also highlighted...
  15. ncbi request reprint Targeted therapy for metastatic melanoma
    Ravi K Amaravadi
    Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA 19104, USA
    Clin Adv Hematol Oncol 5:386-94. 2007
  16. ncbi request reprint The roles of therapy-induced autophagy and necrosis in cancer treatment
    Ravi K Amaravadi
    Abramson Cancer Center at the University of Pennsylvania, Philadelphia, PA 19104, USA
    Clin Cancer Res 13:7271-9. 2007
    ..The effect of tumor cell autophagy and necrosis on host immunity is explored. Finally, therapeutic approaches that target autophagy and necrosis in cancer are described...
  17. ncbi request reprint The MAPK pathway in melanoma
    Leslie A Fecher
    University of Pennsylvania, Division of Hematology and Oncology, Department of Medicine, The Abramson Cancer Center, Philadelphia, Pennsylvania 19104, USA
    Curr Opin Oncol 20:183-9. 2008
    ..Several therapeutic agents directed against this pathway are in development. This review summarizes current understanding of the MAPK pathway in melanoma biology and therapeutic strategies...
  18. ncbi request reprint Autophagy: a targetable linchpin of cancer cell metabolism
    Robert D Leone
    Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA
    Trends Endocrinol Metab 24:209-17. 2013
    ....
  19. pmc Autophagy inhibition enhances therapy-induced apoptosis in a Myc-induced model of lymphoma
    Ravi K Amaravadi
    Division of Hematology Oncology, Department of Medicine, Abramson Family Cancer Research Institute, Philadelphia, Pennsylvania 19104, USA
    J Clin Invest 117:326-36. 2007
    ....